Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics Stock (NASDAQ: AUTL) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range1.600 - 5.040 | Open / Close- / - | Float / Outstanding- / 173.059M |
Vol / Avg.0 / 627.863K | Mkt Cap358.233M | P/E- | 50d Avg. Price2.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float- | EPS-1.850 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-09 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | ||||||
REV | 2.369M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on Friday, December 9, 2022. The analyst firm set a price target for 7.00 expecting AUTL to rise to within 12 months (a possible 238.16% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $2.07 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics’s Q4 earnings are confirmed for Thursday, March 9, 2023.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.